DelveInsight’s “Acute Liver Failure Market Insight, Epidemiology and Market Forecast 2032” report provides current treatment practices, emerging drugs, Acute Liver Failure market share of the individual therapies, current and forecasted Acute Liver Failure market size from 2019 to 2032 segmented by seven major markets. The report also offers current Acute Liver Failure therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute Liver Failure market.
Acute Liver Failure Overview
Acute liver failure (ALF) is the development of sudden, severe hepatic dysfunction from an acute insult to the liver, associated with the onset of hepatic encephalopathy and coagulation abnormalities. American Association for the Study of Liver Diseases (AASLD) defines it as the evidence of coagulation abnormality, usually an international normalized ratio above 1.5, and any degree of mental alteration (encephalopathy) in a patient without preexisting liver disease and with an illness of less than 26 weeks’ duration.
The condition is categorized into three categories based on the interval between the development of jaundice and the onset of encephalopathy. The first is hyperacute liver failure in which the onset of encephalopathy is within seven days after the development of jaundice. Second, acute liver failure in which the onset of encephalopathy is within eight to 28 days after the development of jaundice and the third, sub-acute liver failure in which the onset of encephalopathy is inmore than 5 weeks but less than 12 weeks after the development of jaundice.
A diverse array of etiologies can cause ALF which include drugs and toxins like Acetaminophen, Amanita phalloides; viral infections like Hepatis A, B, E; vascular problems like shock, heat stroke, tumor infiltrating the liver; metabolic etiologies like Wilson’s disease, acute fatty liver of pregnancy, autoimmune hepatitis and others. Also, in many cases, the cause of acute liver failure remains unknown.
Acute Liver Failure Epidemiological Insights
As per Delvelnsight’s analysis, women are more likely to present with drug- induced hepatotoxicity and acute liver failure than are men.
Acute Liver Failure Treatment Market
The treatment of ALF is supportive and symptomatic management with aim to identify and treat the underlying etiology, like Acetaminophen-induced hepatotoxicity, drug-induced hepatotoxicity, mushroom poisoning, viral hepatitis, The treatment involves management of neurological dysfunction i.e. hepatic encephalopathy (HE), prevention and treatment of cerebral edema and intracranial hypertension, management of coagulopathy, renal dysfunction, Correction of metabolic abnormalities and providing nutritional support.
Promising Therapies in the Acute Liver Failure Pipeline
Discover more about Acute Liver Failure therapies in the pipeline @ Acute Liver Failure Drugs
Leading Companies Working in the Acute Liver Failure Market
To understand key companies related to the Acute Liver Failure Market, get a snapshot of the Acute Liver Failure Regulatory and Patent Analysis.
Scope of the Acute Liver Failure Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Acute Liver Failure Companies: Akaza Biosciences, and others
Key Acute Liver Failure Pipeline Therapies: Resatorvid (TAK-242), and others
Therapeutic Assessment: Acute Liver Failure current marketed and emerging therapies
Acute Liver Failure Market Dynamics: Acute Liver Failure market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Acute Liver Failure Market Access and Reimbursement
Table of Contents
1. Acute Liver Failure Market Key Insights
2. Acute Liver Failure Market Report Introduction
3. Acute Liver Failure Market Overview at a Glance
4. Acute Liver Failure Market Executive Summary
5. Disease Background and Overview
6. Acute Liver Failure Treatment and Management
7. Acute Liver Failure Epidemiology and Patient Population
8. Patient Journey
9. Acute Liver Failure Emerging Drugs
10. 7MM Acute Liver Failure Market Analysis
11. Acute Liver Failure Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Acute Liver Failure Market Drivers
15. Acute Liver Failure Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Report Offerings by DelveInsight:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Kritika Rehani
[email protected]
+1(919)321-6187
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
